Literature DB >> 15271177

Obstructive sleep apnoea and cardiovascular disease.

G S Hamilton1, P Solin, M T Naughton.   

Abstract

Obstructive sleep apnoea (OSA) leads to both acute and chronic physiological effects on the cardiovascular system. There is now a large amount of evidence showing that OSA is independently associated with a wide spectrum of clinical cardiovascular disease (CVD). Evidence for a causative effect of OSA is strongest for hypertension, but is weaker for other cardiovascular disorders. Large prospective trials are ongoing and when results become available the link between OSA and CVD is likely to be strengthened. Treatment of OSA with continuous positive airway pressure has been shown to improve blood pressure, particularly in those with hypertension, and also left ventricular ejection fraction in those with congestive heart failure. Given the high prevalence of OSA in the community and its effects on the cardiovascular system, symptoms of this disorder should be sought in patients being investigated or treated for CVD.

Entities:  

Mesh:

Year:  2004        PMID: 15271177     DOI: 10.1111/j.1445-5994.2004.00596.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  26 in total

1.  Augmented cardiovascular responses to episodes of repetitive compared with isolated respiratory events in preschool children with sleep-disordered breathing.

Authors:  Lisa M Walter; Sarah N Biggs; Lauren C Nisbet; Aidan J Weichard; Milou Muntinga; Margot J Davey; Vicki Anderson; Gillian M Nixon; Rosemary S C Horne
Journal:  Pediatr Res       Date:  2015-08-13       Impact factor: 3.756

2.  Energy expenditure in obstructive sleep apnea: validation of a multiple physiological sensor for determination of sleep and wake.

Authors:  Denise M O'Driscoll; Anthony R Turton; Janet M Copland; Boyd J Strauss; Garun S Hamilton
Journal:  Sleep Breath       Date:  2012-02-10       Impact factor: 2.816

3.  Rapid reduction of antihypertensive medications and insulin requirements after tracheostomy in a patient with severe obstructive sleep apnea syndrome.

Authors:  Arvind Bhimaraj; Navasuma Havaligi; Siva Ramachandran
Journal:  J Clin Sleep Med       Date:  2007-04-15       Impact factor: 4.062

4.  Validation of a portable monitor for the diagnosis of obstructive sleep apnea in morbidly obese patients.

Authors:  Jan Magnus Fredheim; J Røislien; J Hjelmesæth
Journal:  J Clin Sleep Med       Date:  2014-07-15       Impact factor: 4.062

5.  CrossTalk opposing view: Loop gain is not a consequence of obstructive sleep apnoea.

Authors:  J E Orr; B A Edwards; A Malhotra
Journal:  J Physiol       Date:  2014-07-15       Impact factor: 5.182

6.  Preschool children with obstructive sleep apnea: the beginnings of elevated blood pressure?

Authors:  Lauren C Nisbet; Stephanie R Yiallourou; Sarah N Biggs; Gillian M Nixon; Margot J Davey; John A Trinder; Lisa M Walter; Rosemary S C Horne
Journal:  Sleep       Date:  2013-08-01       Impact factor: 5.849

7.  Sleep and diabetes.

Authors:  Swetha Bopparaju; Salim Surani
Journal:  Int J Endocrinol       Date:  2010-03-09       Impact factor: 3.257

8.  Diagnostic performance of single airflow channel recording (ApneaLink) in home diagnosis of sleep apnea.

Authors:  Regine Ragette; Yi Wang; Gerhard Weinreich; Helmut Teschler
Journal:  Sleep Breath       Date:  2009-08-28       Impact factor: 2.816

9.  Evaluation of a single-channel nasal pressure device to assess obstructive sleep apnea risk in laboratory and home environments.

Authors:  Kate E Crowley; Shantha M W Rajaratnam; Steven A Shea; Lawrence J Epstein; Charles A Czeisler; Steven W Lockley
Journal:  J Clin Sleep Med       Date:  2013-02-01       Impact factor: 4.062

10.  Acute cardiovascular changes with obstructive events in children with sleep disordered breathing.

Authors:  Denise M O'Driscoll; Alison M Foster; Michelle L Ng; Joel S C Yang; Farhat Bashir; Gillian M Nixon; Margot J Davey; Vicki Anderson; Adrian M Walker; John Trinder; Rosemary S C Horne
Journal:  Sleep       Date:  2009-10       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.